替奈普酶超说明书用于急性缺血性卒中:系统评价与Meta分析
该系统评价与Meta分析检索MEDLINE和Scopus(2021年10月12日),纳入6项非随机研究、共1820例急性缺血性卒中患者(618例[34%]接受替奈普酶),比较静脉替奈普酶(任意剂量)与静脉阿替普酶。替奈普酶组3个月良好功能结局(mRS 0-2)粗OR 1.22(95%CI 0.90-1.66)、调整OR 1.60(95%CI 1.08-2.37),成功再通粗OR 2.82(95%CI 1.12-7.10)、调整OR 2.38(95%CI 1.18-4.81),早期神经功能改善粗OR 4.88(95%CI 2.03-11.71)、调整OR 7.60(95%CI 1.97-29.41)。3个月极好功能结局(mRS 0-1)、症状性颅内出血及实质血肿均无显著差异。作者认为替奈普酶与阿替普酶安全性相当,可能改善功能结局,继续入组正在进行的RCT是合适的。
要点
- 替奈普酶组3个月良好功能结局调整OR 1.60(95%CI 1.08-2.37),粗OR 1.22(95%CI 0.90-1.66)。
- 替奈普酶组成功再通粗OR 2.82(95%CI 1.12-7.10)、调整OR 2.38(95%CI 1.18-4.81)。
- 替奈普酶组早期神经功能改善粗OR 4.88(95%CI 2.03-11.71)、调整OR 7.60(95%CI 1.97-29.41)。
- 3个月极好功能结局(mRS 0-1)、症状性颅内出血、实质血肿两组均无显著差异。
- 作者认为继续入组正在进行的RCT是合适的。
适用人群与场景
- 非随机研究(前瞻性或回顾性)纳入的急性缺血性卒中患者,比较静脉替奈普酶(任意剂量)与静脉阿替普酶。
研究设计与关键结果
- 研究类型:系统评价与Meta分析,遵循PRISMA指南和MOOSE提案,采用随机效应模型合并估计值;共纳入6项非随机研究、1820例患者(618例[34%]接受替奈普酶)。
- 主要终点:3个月良好功能结局(mRS 0-2),替奈普酶组粗OR 1.22(95%CI 0.90-1.66),调整OR 1.60(95%CI 1.08-2.37)。
- 成功再通:替奈普酶组粗OR 2.82(95%CI 1.12-7.10),调整OR 2.38(95%CI 1.18-4.81)。
- 早期神经功能改善:替奈普酶组粗OR 4.88(95%CI 2.03-11.71),调整OR 7.60(95%CI 1.97-29.41)。
- 3个月极好功能结局(mRS 0-1):替奈普酶组粗OR 1.53(95%CI 0.81-2.91),调整OR 2.51(95%CI 0.66-9.49),无显著差异。
- 症状性颅内出血:替奈普酶组粗OR 0.97(95%CI 0.44-2.16),调整OR 1.16(95%CI 0.13-10.50),无显著差异。
- 实质血肿:替奈普酶组粗OR 1.20(95%CI 0.24-5.95),无显著差异。
证据类型、等级与局限
- 证据类型:系统评价与Meta分析,纳入非随机研究(前瞻性或回顾性)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,基于这些非随机研究证据,替奈普酶与阿替普酶安全性相当,且可能与改善功能结局相关,继续入组正在进行的随机临床试验是合适的。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Tenecteplase is being evaluated as an alternative thrombolytic agent for the treatment of acute ischemic stroke (AIS) within ongoing randomized clinical trials (RCTs). In addition, nonrandomized clinical experiences with off-label use of tenecteplase vs alteplase for AIS treatment are being published.
OBJECTIVE: To evaluate the available evidence on the safety and efficacy of intravenous tenecteplase compared with intravenous alteplase provided by nonrandomized studies.
DATA SOURCES: Eligible studies were identified by searching MEDLINE and Scopus databases. No language or other restrictions were imposed. The literature search was conducted on October 12, 2021. This meta-analysis used the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and was written according to the Meta-analysis of Observational Studies in Epidemiology (MOOSE) proposal.
STUDY SELECTION: Nonrandomized studies (prospective or retrospective) comparing intravenous tenecteplase (at any dose) with intravenous alteplase in patients with AIS were included in the analysis.
DATA EXTRACTION AND SYNTHESIS: The crude odds ratios (ORs) and 95% CIs were calculated for the association of tenecteplase vs alteplase with the outcomes of interest and adjusted ORs were extracted if provided. Estimates using random-effects models were pooled.
MAIN OUTCOMES AND MEASURES: The primary outcome was the probability of good functional outcome (modified Rankin scale [mRS] score, 0-2) at 90 days.
RESULTS: Six studies were identified including a total of 1820 patients (618 [34%] treated with tenecteplase). Patients receiving tenecteplase had higher odds of 3-month good functional outcome (crude odds ratio [OR], 1.22; 95% CI, 0.90-1.66; adjusted OR, 1.60, 95% CI, 1.08-2.37), successful recanalization (crude OR, 2.82; 95% CI, 1.12-7.10; adjusted OR, 2.38; 95% CI, 1.18-4.81), and early neurological improvement (crude OR, 4.88; 95% CI, 2.03-11.71; adjusted OR, 7.60; 95% CI, 1.97-29.41). No significant differences were detected in 3-month excellent functional outcome proportions (mRS score 0-1; crude OR, 1.53; 95% CI, 0.81-2.91; adjusted OR, 2.51; 95% CI, 0.66- 9.49), symptomatic intracranial hemorrhage (crude OR, 0.97; 95% CI, 0.44-2.16; adjusted OR, 1.16; 95% CI, 0.13-10.50), or parenchymal hematoma (crude OR, 1.20; 95% CI, 0.24-5.95).
CONCLUSIONS AND RELEVANCE: Evidence from nonrandomized studies suggests tenecteplase is as safe as alteplase and potentially associated with improved functional outcomes compared with alteplase. Based on these findings, enrollment in the ongoing RCTs appears to be appropriate.
参考来源
- Katsanos AH, Psychogios K, Turc G, et al. Off-Label Use of Tenecteplase for the Treatment of Acute Ischemic Stroke: A Systematic Review and Meta-analysis. JAMA Netw Open. 2022. PMID: 35357458. doi:10.1001/jamanetworkopen.2022.4506
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。